Extracranial Size in Patients with Schizophrenia
نویسندگان
چکیده
Much of the current literature from both neuroimaging and post mortem studies points to a reduction in intracranial size and cerebrum in schizophrenia. Intriguingly, there is also evidence for reduced extracranial size in infants at high risk for schizophrenia, while studies in adults with schizophrenia which have assessed head size have been inconclusive. Using head measures of circumference, length and width derived from caliper examination in both coronal and saggital planes, we examined head size in 46 male controls (mean age 42 6 9 years; 20 Caucasian, 26 African American) and 44 patients (mean age 40 6 9 years; 18 Caucasian, 26 African American) with DSM-IV schizophrenia. In a linear regression model which entered race and diagnosis as independent factors and stature and elbow breadth as covariates, we found no evidence for reduced extracranial size in schizophrenia. These data suggest that the process(es) which underlie smaller brains in schizophrenia do not produce a corresponding reduction in head size.
منابع مشابه
تخمین شناختی در بیماران مبتلا به اختلال اسکیزوفرنی، افسردگی اساسی و افراد بهنجار
Background and Objective: Estimation abilities are a group of processes that involve cognitive functions such as planning, attention, abstract reasoning, and memory. The goal of this study was to assess cognitive estimation in patients with schizophrenia, major depression disorder (MDD) and normal individuals. Materials and Methods: Three groups including patients with schizophrenia, m...
متن کاملThe Effects of Bupropion on Negative Symptoms in Schizophrenia
Abstract:Purpose:This study was designed determine the efficacy of bupropion versus placebo in subjects with negative symptoms of schizophrenia.Methods:A convenience sample of 40 patients of both genders aged 18-60 years who were living in psychiatric care centers were randomly treated with bupropion (started with 75 mg twice a day; increased to 100 mg thrice daily) or placebo. The diagnosis of...
متن کاملEfficacy of Risperidone Augmentation with Ondansetron in the Treatment of Negative and Depressive Symptoms in Schizophrenia: A Randomized Clinical Trial
Background: Given the potential role of the 5-hydroxytryptamine-3 receptor in the pathogenesis of schizophrenia, this study was performed to determine whether ondansetron plus risperidone could reduce the negative and depressive symptoms in patients with treatment-resistant schizophrenia.Methods: In a double-blinded, placebo-controlled, randomized trial (IRCT registration # 201112125280N7), in ...
متن کاملEvaluation of the efficacy and safety of pregabalin as an adjuvant to antipsychotics in patients with chronic schizophrenia: a six-week pilot double-blind placebo-controlled trial
Introduction and objectives: Antipsychotics or dopamine receptor antagonists are the major components of treatment but about 10-20% of patients with schizophrenia do not benefit from treatment with antidopaminergic agents, indicating other neuronal systems may be involved in this disorder (2). Dysregulation of both excitatory and inhibitory mechanisms N-Methyl-D-aspartic acid (NMDA) and γ-Amino...
متن کاملCOMPARISON OF THE QUALITY OF LIFE IN PATIENTS WITH MAJOR DEPRESSION AND SCHIZOPHRENIA IN THE PARTIAL RECOVERY PHASE
Background & Aims: Schizophrenia and major depression are among severe and chronic psychiatric disorders that affect the most important area of a person's life, namely quality of life. Quality of life is very important in patients with chronic psychiatric disorders and is still low even after partial recovery. Today, quality of life is considered as one of the most important consequences of tre...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2000